

PERSONAL INFORMATION



Stefania Stella

📍 Via del Potatore, 56/B, 95121 Catania

☎ 095 3781946

✉ stefania.stel@gmail.com - stefania.stella@unict.it

PEC: stella.stefania@pec.it

Sex F | Date of birth 05/07/1978 | Nationality Italy

WORK EXPERIENCE

from January 1st 2022 - to date

Assistant Professor in Clinical Pathology (SSD MED/05)

Department Clinical and Experimental Medicine, Center of Experimental Oncology and Haematology, A.O.U. Policlinico "G. Rodolico - San Marco", Catania, Italy.

Research Project: "Prognostic and therapeutic classification of multiple solid tumors through the identification of rare molecular alterations with innovative new generation technologies".

from March 26th 2021 - December 31th 2021

Research Fellow

Research Project: "Characterization of molecular alterations on primary cells isolated from breast cancer patients".

Department Clinical and Experimental Medicine, Center of Experimental Oncology and Haematology, A.O.U. Policlinico "G. Rodolico - San Marco", Catania, Italy. Supervisor: Prof.re P.Vigneri.

- Sequencing analysis by "Next Generation Sequencing" (NGS), using the Ion Torrent PGM and Ion Studio S5 Plus Platforms to evaluate the mutational status: *i.* *BRCA1/2* genes in patients with hereditary - familial syndromes; *ii.* *TP53* mutational status in patients with Chronic Lymphocytic Leukemia.

Business or sector: Molecular oncology and haematology

from March 2021 - to date

P.I. Research Project

Research Project: "Oncomine BRCA1/2 Research assay panel vs QIAseq Target DNA - Human BRCA1 and BRCA2 panel Qiagen for mutational screening of BRCA1/2 genes in breast cancer".

Business or sector: Molecular oncology

from June 2019 - March 25th 2021

Research Fellow

Research Project: "Next-Generation Sequencing for BCR-ABL KD Mutation Screening in Philadelphia chromosome-positive Leukemias".

Department Clinical and Experimental Medicine, Center of Experimental Oncology and Haematology, A.O.U. Policlinico "G. Rodolico - San Marco", Catania, Italy. Supervisor: Prof.ssa L.Manzella.

- Sequencing analysis by NGS, using the Ion Torrent PGM and Ion Studio S5 Plus Platforms to evaluate the mutational status: *i.* *BCR-ABL* KD Mutation Screening in Philadelphia chromosome-positive Leukemias; *ii.* *BRCA1/2* genes in patients with hereditary - familial syndromes; *iii.* *TP53* mutational status in patients with Chronic Lymphocytic Leukemia; *iv.* 12, 18, 19, 20 and 21 EGFR exons in

patients with Non-Small Cell Lung Carcinoma (NSCLC) on circulating free DNA isolated from peripheral blood.

Business or sector: Molecular oncology and haematology

from November 2011 - May 2019

Post Doctoral Fellow in Molecular and cellular Biology

Department Clinical and Experimental Medicine, Center of Experimental Oncology and Haematology, A.O.U. Policlinico - Vittorio Emanuele, Catania, Italy. Supervisor: Prof. F. Di Raimondo.

Diagnostic and Research Activities in Molecular Biology and Applied Biochemistry

- Monitoring of the *BCR-ABL 1* transcript levels by Real Time PCR in CML patients;
- CML Resistance to Imatinib Mesylate: Early Molecular Characterizaion and Alternative Therapeutic Approaches;
- Biological characterization of nuclear function of BCR-ABL protein;
- Biological evaluation of citotoxic effects of Shepherdin in CML resistant cell lines;
- Mechanism of Survivin suppression induced by a *BCR-ABL/JAK2/STAT3* pathway that sensitizes Imatinib-Resistant CML cells to different cytotoxic drugs;
- Mutational analysis by clonal sequencing in CML patients resistant to TKIs therapy.

Business or sector: Molecular oncology and haematology

from November 2008 - October 2011

Ph.D. in Medical Embriology, Sperimental Pathology and Hematology

Department of Biological Chemistry, Medical Chemistry and Molecular Biology - University of Catania.

from May 2004 - July 2008

Research Collaboration Contract

Department of Clinical and Molecular Bio-Medicine, University of Catania, Italy. Supervisor: Prof. A. Messina.

Diagnostic and Research Activities in Molecular Biology and Applied Biochemistry

- Monitoring of the *BCR-ABL 1* transcript levels by Real Time PCR in CML patients;
- CML Resistance to Imatinib Mesylate: Early Molecular Characterizaion and Alternative Therapeutic Approaches;
- Biological characterization of nuclear function of BCR-ABL protein;
- Ex-vivo isolation, purification and culture of myeloid cd34+ derived from bone marrow of 35 CML patients;
- Clinical study of the anti-apoptotic role of the BCR-ABL oncoprotein in CML cells;
- Mutational analysis by clonal sequencing in CML patients resistant to TKIs therapy.

Business or sector: Molecular oncology and haematology

TEACHING ACTIVITY
from May 2016 - today

Teaching Activity

University of Catania

- Master I level "Bio-molecular analysis techniques applied to laboratory investigations in the bio-medical and forensic fields", Module "Metodiche cellulari e Molecolari nella Diagnostica Oncologica" (AA 2015-2016);
- Teaching of GENERAL PATHOLOGY APPLIED TO TRIALS module of the I.C. of Clinical Methodology applied to research studies at the Master's degree course in Nursing and Midwifery Sciences (AA 2017/18; 2018/19; 2019/20, 2020/21, 2021/22);
- Teaching of GENERAL PATHOLOGY module of the I.C. of General Pathology, Clinical Biochemistry and Microbiology at the degree course in Dietetics (AA 2017/2018; 2019/20; 2020/21; 2021/22);
- Teaching of GENERAL PATHOLOGY AND PHYSIOPATHOLOGY module of the I.C. of Bases of Physiology and Pathology (MED / 04) at the degree course in Physiotherapy (AA 2018/2019);
- Teaching of GENERAL AND CLINICAL PATHOLOGY module of the I.C. of General and Clinical Pathology, Microbiology and Pathological Anatomy at the degree course in Nursing (AA 2020/21; 2021/22).

EDUCATION AND TRAINING

from November 2008 - October 2011

Ph.D. in Medical Embriology, Sperimental Pathology and Haematology

Livello QEQ: 8

Department of Biological Chemistry, Medical Chemistry and Molecular Biology - University of Catania.

Supervisor: Prof. L. Manzella and Prof. F. Di Raimondo

PhD thesis: Alternative Therapeutic Approaches for the Treatment of CML resistance Cells to Imatinib Mesylate.

- Monitoring of the BCR-ABL transcript by Real Time PCR in CML patients of Sicily and Calabria Regions;
- Biological characterization of nuclear function of BCR-ABL protein;
- Biological evaluation of citotoxic effects of Shepherdin in CML resistant cell lines.

Livello QEQ: 8

from October 2005 - October 2008

Specialization in Hospital Pharmacy

Department of Pharmaceutical Sciences, Faculty of Pharmacy - University of Messina.

Experimental thesis: Monitoring of the Chronic Myeloid Leukemia Treatment in Sicily Region

- Monitoring of the BCR-ABL transcript by Real Time PCR in CML patients;
- Clinical study of the anti-apoptotic role of the BCR-ABL oncoprotein in CML cells;
- CML Resistance to Imatinib Mesylate: Early Molecular Characterizaion and Alternative Therapeutic Approaches.

from October 1997 - July 2003

Master Degree in Pharmaceutical Chemistry and Technology

Livello QEQ: 7

Department of Biological Chemistry, Medical Chemistry and Molecular Biology. Faculty of Pharmacy - University of Catania.

Supervisor: Prof. M. Renis

Experimental Thesis: Rufloxacin induced photosensitization in bio-models of increasing complexity.

- Technique of Comet Assay, immortalized and primary cell cultures.

PERSONAL SKILLS

Mother tongue(s) Italian

Other language(s)

	UNDERSTANDING		SPEAKING		WRITING
	Listening	Reading	Spoken interaction	Spoken production	
English	B2	B2	B2	B2	B2

Levels: A1/2: Basic user - B1/2: Independent user - C1/2 Proficient user
Common European Framework of Reference for Languages

Communication skills

Excellent interpersonal skills being endowed with a remarkable team spirit and a high ability to adapt to new work environments. Excellent communication skills, achieved thanks to my experience of public exhibitions in various scientific meetings and congresses.

Organisational / managerial skills

Excellent organizational and management skills acquired in the laboratory:
▪ leadership (currently responsible for a team of 5 people)

Job-related skills	<p>Good ability to organize and write a scientific manuscript in English and GRANT proposal. Good knowledge in molecular biology techniques applied to the study of gene expression.</p> <p>Cell biology: Purification of bacterial strains, Bacterial Cultures Isolation, DNA cloning in Plasmid, Retroviral and Lentiviral vectors, Transfection and viral infection of immortalized and primary cells extracted from healthy patients and donors, Gene silencing through the use of shRNA and siRNA Immortalized and primary cell cultures, Cell count and cryopreservation of cell cultures, Isolation of progenitors from peripheral blood; Isolation of CD34+ progenitor from donors; Methylcellulose assays.</p> <p>Molecular biology: Probe e Primer design, PCR, nested PCR, RT-PCR, Real-Time PCR, Next Generation Sequencing, Sanger Sequencing, Genomic and plasmid DNA Extraction, RNA Extraction, Restriction Enzyme Digestion, Mutational Screenings, cell free DNA isolation, analysis of DPYD variants, analysis of the UGT1A1 genotype, EGFR Therascreen analysis, Mutational analysis by clonal sequencing of patients with chronic myeloid leukemia resistant to current therapy, Next Generation Sequencing, using the Ion Torrent PGM and Ion Studio S5 Plus Platforms to evaluate the mutational status.</p>
Computer skills	<p>Excellent command of:</p> <ul style="list-style-type: none"> - Operating systems: Windows and Macintosh; - Application packages: Microsoft office (Word, Excel, Powerpoint, Entourage, Outlook), Adobe Photoshop, Macromedia Freehand, Adobe Illustrator, Gene Works, Oligo 6.0.1., Internet browsers (Microsoft Explorer, Netscape Navigator, Safari, Firefox); - Software for NGS: GS Amplicon Variant Analyzer and Ion Reporter Software; - Clinical variant analysis database: COSMIC, dbSNP, ClinVar; - Bioinformatics tools (BLAST, PrimerBLAST, PrimerExpress, PerlPrimer, ClustalW); - Software for the prediction of the functional effects of human nsSNPs: PolyPhen-2, Mutation Taster, SIFT, FATHMM. Software for the analysis of intracellular signaling pathways: Panther, DAVID bioinformatic resources, STRING.
Driving licence	<p>Driving licence category/-ies:</p> <ul style="list-style-type: none"> ▪ A1 ▪ B

ADDITIONAL INFORMATION

SCIENTIFIC PRIZE 2021	<p>Prize “Associazione Italiana contro Leucemie Linfomi e Mielomi (AIL) - Catania “ “Miglior percorso come giovane ricercatore nel campo dei meccanismi patogenetici alla base delle patologie oncoematologiche”.</p>
Publications	<ol style="list-style-type: none"> 1. Alfio Catalfo, Christian Scifo, Stefania Stella, Alessandra Belvedere, Marcella Renis and Guido De Guidi. <i>Rifloxacin induced photosensitization in bio-models of increasing complexity. Photochemical and Photobiological Sciences.</i> 2005 Marzo 4(3): 304-314. Impact Factor: 3,982. 2. Brown EE, Whitby D, Vitale F, Fei PC, Del Carpio C, Marshall V, Alberg AJ, Serraino D, Messina A, Gafa L, Goedert JJ and Classical Kaposi Sarcoma Working Group (Stefania Stella). <i>Correlates of Human Herpesvirus-8 DNA detection among adults in Italy without Kaposi sarcoma. International Journal of Epidemiology.</i> Ottobre 2005, 34(5): 1110-7. Epub 2005 Jul 25. Impact Factor: 7,196. 3. Brown EE, Fallin D, Ruczinski I, Hutchinson A, Staats B, Vitale F, Lauria C, Serraino D, Rezza G, Mbisa G, Whitby D, Messina A, Goedert JJ, Chanock SJ and Kaposi Sarcoma Genetics Working Group (Stefania Stella). <i>Associations of classic Kaposi sarcoma with common variants in genes that modulate host immunity. Cancer Epidemiol Biomarkers Prev.</i> 2006 May;15(5):926-34. Impact Factor: 4,254.

Publications

4. Fabio Stagno, **Stefania Stella**, Salvatore Berretta, Michele Massimino, Agostino Antolino, Rosario Giustolisi, Angelo Messina, Francesco Di Raimondo, Paolo Vigneri. *Sequential mutations causing resistance to both Imatinib Mesylate and Dasatinib in a chronic myeloid leukaemia patient progressing to lymphoid blast crisis*. *Leukemia Research* 32 (2008) 669–677. **Impact Factor: 3,156.**
5. Fabio Stagno, Paolo Vigneri, Vittorio Del Fabro, **Stefania Stella**, Michele Massimino, Salvo Berretta, Angelo Messina, Francesco Di Raimondo. *Imatinib dose escalation to achieve molecular responses in patients with chronic myeloid leukemia in late chronic phase*. *Leukemia Research* 2009 Jun;33(6): e17. Epub 2008 Nov 25. **Impact Factor: 3,156.**
6. Fabio Stagno, Paolo Vigneri, Vittorio Del Fabro, **Stefania Stella**, Michele Massimino, Salvatore Berretta, Alessandra Cupri, Carla Consoli, Luigi Messina, Elena Tirrò, Angelo Messina, Francesco Di Raimondo. *Successful Nilotinib therapy in an imatinib-resistant chronic myeloid leukemia patient displaying an intron-derived insertion/truncation mutation in the BCR-ABL kinase domain*. *Leukemia Research* 2009 Sep;33(9):157-8. Epub 2009 Apr 29. **Impact Factor: 3,156.**
7. Fabio Stagno, Paolo Vigneri, Vittorio Del Fabro, **Stefania Stella**, Salvatore Berretta, Michele Massimino, Elena Tirrò, Angelo Messina, Francesco Di Raimondo. *Uncommon long-term survival in a patient with chronic myeloid leukemia*. *Acta Oncol.* 2009 Aug 27:1-2. **Impact Factor: 4,089.**
8. Fabio Stagno, Paolo Vigneri, Vittorio Del Fabro, **Stefania Stella**, Nunzio Restuccia, Caterina Giallongo, Michele Massimino, Salvatore Berretta, Maria Stella Pennisi, Daniele Tibullo, Elena Tirrò, Calogero Buscarino, Angelo Messina, Francesco Di Raimondo. *Concomitant and feasible treatment with dasatinib and the anti-EGFR antibody cetuximab plus radiotherapy in a CML patient with multiple squamous neoplasias*. *Acta Oncol.* 2010;49(1):109-10. **Impact Factor: 4,089.**
9. Fabio Stagno, Paolo Vigneri, Vittorio Del Fabro, **Stefania Stella**, Alessandra Cupri, Michele Massimino, Carla Consoli, Loredana Tambè, Maria Letizia consoli, Agostino Antolino, Francesco di Raimondo. *Influence of complex variant chromosomal translocations in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors*. *Acta Oncol.* 2010 May;49(4):506-8. **Impact Factor: 4,089.**
10. Fabio Stagno, Paolo Vigneri, Maria Letizia Consoli, Alessandra Cupri, **Stefania Stella**, Loredana Tambè, Michele Massimino, Livia Manzella, Francesco Di Raimondo. *Hyperdiploidy associated with a high BCR-ABL transcript level may identify patients at risk of progression in chronic myeloid leukemia*. *Acta Haematol.* 2012;127(1):7-9. **Impact Factor: 2,195.**
11. Barbara Tomasello, Salvatore Grasso, Giuseppe La Malfa, **Stefania Stella**, Marco Favetta, Marcella Renis. *Double-face activity of resveratrol in voluntary runners: assessment of DNA damage by comet assay*. *J Med Food.* 2012 May;15(5):441-7. **Impact Factor: 2,786.**
12. Fabio Stagno, Paolo Vigneri, Alessandra Cupri, **Stefania Stella**, Francesco Di Raimondo. *Personalized strategies for CML patients considering discontinuation of tyrosine kinase inhibitors treatment*. *Leuk Res.* 2012 Sep;36(9):1208-9. **Impact Factor: 3,156.**
13. **Stefania Stella**, Elena Tirrò, Enrico Conte, Fabio Stagno, Francesco Di Raimondo, Livia Manzella, Paolo Vigneri. *Suppression of Survivin Induced by a BCR-ABL/JAK2/STAT3 Pathway Sensitizes Imatinib-Resistant CML Cells to Different Cytotoxic Drugs*. *Mol Cancer Ther.* 2013 Jun;12(6):1085-98. **Impact Factor: 6,261.**
14. Michele Massimino, Maria L. Consoli, Maria Mesuraca, Fabio Stagno, Elena Tirrò, **Stefania Stella**, Maria S. Pennisi, Chiara Romano, Pietro Buffa, Heather M.Bond, Giovanni Morrone, Laura Sciacca, Francesco Di Raimondo, Livia Manzella and Paolo Vigneri. *IRF5 is a target of BCR-ABL kinase activity and reduces CML cell proliferation*. *Carcinogenesis* 2014 May;35(5):1132-43. **Impact Factor: 4,944.**
15. Paolo Giovanni Vigneri, Elena Tirrò, Maria Stella Pennisi, Michele Massimino, Stefania Stella, Chiara Romano, Livia Manzella. *The Insulin/IGF System in Colorectal Cancer Development and Resistance to Therapy*. *Front Oncol.* 2015 Oct 15;5:230. **Impact Factor: 6,244.**
16. Paolo Vigneri, Federica Martorana, Livia Manzella and **Stefania Stella**. *Biomarkers and Prognostic Factors for Malignant*. *Future Oncology.* *Future Oncol.* 2015 Nov;11(24 Suppl):29-33. Review. **Impact Factor: 3,404.**
17. Livia Manzella, Elena Tirrò, Maria Stella Pennisi, Michele Massimino, **Stefania Stella**, Chiara Romano, Silvia Rita Vitale and Paolo Vigneri. *Roles of Interferon Regulatory Factors in Chronic Myeloid Leukemia*. *Curr Cancer Drug Targets.* 2016;16(7):594-605. Review. **Impact Factor: 3,428.**

18. Fabio Stagno, **Stefania Stella**, Antonio Spitaleri, Maria Stella Pennisi, Francesco Di Raimondo F and Paolo Vigneri. *Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes*. Expert Rev Anticancer Ther. 2016; 16(3):273-8. Review. **Impact Factor: 4,512.**
19. Livia Manzella, **Stefania Stella**, Maria Stella Pennisi, Elena Tirrò, Michele Massimino, Chiara Romano, Adriana Puma and Paolo Vigneri. *New Insights in Thyroid Cancer and p53 Family Proteins*. Int J Mol Sci. 2017 Jun 21;18(6). Review. **Impact Factor: 5,923.**
20. Paolo Vigneri, Fabio Stagno, **Stefania Stella (co-first author)**, Alessandra Cupri, Stefano Forte, Michele Massimino, Agostino Antolino, Sergio Siragusa, Donato Mannina, Stefania stella Impera, Caterina Musolino, Alessandra Malato, Giuseppe Mineo, Carmela Tomaselli, Pamela Murgano, Maurizio Musso, Fortunato Morabito, Stefano Molica, Bruno Martino, Livia Manzella, Martin C. Müller, Andreas Hochhaus and Francesco Di Raimondo. *HIGH BCR-ABL/GUSIS Levels At Diagnosis Of Chronic phase CML Are Associated With Unfavorable Responses To Standard-Dose Imatinib*. Clin Cancer Res 2017 Dec 1;23(23):7189-7198. **Impact Factor: 12,531.**
21. Michele Massimino, **Stefania Stella (co-first author)**, Elena Tirrò, Chiara Romano, Maria Stella Pennisi, Adriana Puma, Livia Manzella, Antonino Zanghì, Fabio Stagno, Francesco Di Raimondo and Paolo Vigneri. *Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia*. Mol Cancer Feb 2018; 17:56. Review. **Impact Factor: 27,401.**
22. Maria Cristina Piroso, Salvatore Leotta, **Stefania Stella**, Enrica Antonia Martino, Luca Scalise, Giuseppe Sapienza, Valeria Calafiore, Elisa Mauro, Andrea Spadaro, Paolo Vigneri, Francesco Di Raimondo and Giuseppe Milone. *Long-Term Molecular Remission Achieved by Antibody Anti-CD22 and Ponatinib in a Patient Affected by Ph⁺ Acute Lymphoblastic Leukemia Relapsed after Second Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report*. Chemotherapy. 2018;63(4):220-224. **Impact Factor: 1,66.**
23. Michele Massimino, Elena Tirrò, **Stefania Stella (co-first author)**, Francesco Frasca, Veronica Vella, Laura Sciacca, Maria Stella Pennisi, Silvia Rita Vitale, Chiara Romano, Adriana Puma and Livia Manzella. *Effect of Combined Epigenetic Treatments and Ectopic NIS Expression on Undifferentiated Thyroid Cancer Cells*. Anticancer Res. 2018 Dec;38(12):6653-6662. **Impact Factor: 2,48.**
24. **Stefania Stella**, Michele Massimino, Elena Tirrò, Silvia Rita Vitale, Luca Scalise, Salvatore Leotta, Maria Stella Pennisi, Adriana Puma, Chiara Romano, Fabio Stagno, Giuseppe Sapienza, Giuseppe Milone and Livia Manzella. *B-ALL Relapses After Autologous Stem Cell Transplantation Associated With a Shift from e1a2 to e14a2 BCR-ABL Transcripts: A Case Report*. Anticancer Res. 2019 Jan;39(1):431-435. **Impact Factor: 2,48.**
25. Elena Tirrò, Michele Massimino, Chiara Romano, Maria Stella Pennisi, **Stefania Stella**, Silvia Rita Vitale, Annamaria Fidilio, Livia Manzella, Nunziatina Laura Parrinello, Fabio Stagno, Giuseppe Alberto Palumbo, Piera La Cava, Alessandra Romano, Francesco Di Raimondo and Paolo G. Vigneri. *Chk1 Inhibition Restores Inotuzumab Ozogamicin Cytotoxicity in CD22-Positive Cells Expressing Mutant p53*. Front Oncol. 2019 Feb 18;9:57. eCollection 2019. **Impact Factor: 6,244.**
26. Elena Tirrò, **Stefania Stella (co-first author)**, Michele Massimino, Valentina Zammit, Maria Stella Pennisi, Silvia Rita Vitale, Chiara Romano, Sandra Di Gregorio, Adriana Puma, Francesco Di Raimondo, Fabio Stagno and Livia Manzella. *Colony-Forming Cell Assay Detecting the Co-Expression of JAK2V617F and BCR-ABL1 in the Same Clone: A Case Report*. Acta Haematol. 2019;141(4):261-267. **Impact Factor: 2,195.**
27. Giuseppe Alberto Palumbo, **Stefania Stella**, Maria Stella Pennisi, Cristina Piroso, Elisa Fermo, Sonia Fabris, Daniele Cattaneo and Alessandra Iurlo. *The Role of NGS in Myeloproliferative Neoplasms*. Front. Oncol. 2019 April 26;):321. eCollection 2019. Review. **Impact Factor: 6,244.**
28. **Stefania Stella**, Valentina Zammit, Silvia Rita Vitale, Maria Stella Pennisi, Michele Massimino, Elena Tirrò, Stefano Forte, Antonio Spitaleri, Agostino Antolino, Sergio Siragusa, Vincenzo Accurso, Donato Mannina, Stefania Impera, Caterina Musolino, Sabina Russo, Alessandra Malato, Giuseppe Mineo, Maurizio Musso, Ferdinando Porretto, Bruno Martino, Francesco Di Raimondo, Livia Manzella, Paolo Vigneri and Fabio Stagno. *Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib*. Int J Mol Sci. 2019 May 6;20(9). pii: E2226. **Impact Factor: 5,923.**
29. Elena Tirrò, Michele Massimino, **Stefania Stella (co-first author)**, Valentina Zammit, Maria Letizia Consoli, Maria Stella Pennisi, Silvia Rita Vitale, Chiara Romano, Enrica Martino, Sandra Di Gregorio, Adriana Puma, Francesco Di Raimondo, Livia Manzella and Fabio Stagno. *Efficacy of*

Nilotinib in a CML Patient Expressing the Three-way Complex Variant Translocation t(2;9;22). Anticancer Res. 2019 Jul;39(7):3893-3899. **Impact Factor: 2,48.**

30. Michele Massimino, **Stefania Stella (co-first author)**, Elena Tirro', Maria Letizia Consoli, Maria Stella Pennisi, Adriana Puma, Silvia Rita Vitale, Chiara Romano, Valentina Zammit, Fabio Stagno, Francesco Di Raimondo and Livia Manzella. *Efficacy of Dasatinib in a Very Elderly CML Patient Expressing a Rare E13a3 Bcr-Abl1 Fusion Transcript: A Case Report.* Anticancer Res. 2019 Jul;39(7):3949-3954. **Impact Factor: 2,48.**
31. Livia Manzella, Michele Massimino, **Stefania Stella (co-first author)**, Elena Tirro' Maria Stella Pennisi, Federica Martorana, Gianmarco Motta, Silvia Rita Vitale, Adriana Puma, Chiara Romano, Sandra Di Gregorio, Marco Russo, Pasqualino Malandrino and Paolo Vigneri. *Activation of the IGF Axis in Thyroid Cancer: Implications for Tumorigenesis and Treatment.* Int J Mol Sci. 2019 Jul 2;20(13). pii: E3258. Review. **Impact Factor: 5,923.**
32. Michele Massimino, **Stefania Stella (co-first author)**, Elena Tirro', Maria Letizia Consoli, Maria Stella Pennisi, Adriana Puma, Silvia Rita Vitale, Chiara Romano, Valentina Zammit, Fabio Stagno, Francesco Di Raimondo and Livia Manzella. *Rapid decline of Philadelphia-positive metaphases after nilotinib treatment in a CML patient expressing a rare e14a3 BCR-ABL1 fusion transcript: A case report.* Oncol Lett. 2019 Sep;18(3):2648-2653. **Impact Factor: 2,967.**
33. Maria Stella Pennisi, **Stefania Stella (co-first author)**, Silvia Rita Vitale, Adriana Puma, Sandra Di Gregorio, Chiara Romano, Elena Tirro', Michele Massimino, Agostino Antolino, Sergio Siragusa, Donato Mannina, Stefana Impera, Caterina Musolino, Giuseppe Mineo, Bruno Martino, Valentina Zammit, Francesco Di Raimondo, Livia Manzella, Fabio Stagno and Paolo Vigneri. *BCR-ABL1 Doubling-Times and Halving-Times May Predict CML Response to Tyrosine Kinase Inhibitors.* Front Oncol. 2019 Aug 13;9:764. **Impact Factor: 6,244.**
34. **Stefania Stella**, Elena Tirrò, Michele Massimino, Silvia Rita Vitale, Sabina Russo, Maria Stella Pennisi, Adriana Puma, Chiara Romano, Sandra Di Gregorio, Vanessa Innao, Fabio Stagno, Francesco Di Raiomondo and Livia Manzella. *Successful Management of a Pregnant Patient With Chronic Myeloid Leukemia Receiving Standard Dose Imatinib.* In Vivo. 2019 Sep-Oct;33(5):1593-1598. **Impact Factor: 2,155.**
35. Elena Tirrò, Federica Martorana, Chiara Romano, Silvia Rita Vitale, Gianmarco Motta, Sandra Di Gregorio, Michele Massimino, Maria Stella Pennisi, **Stefania Stella**, Adriana Puma, Fiorenza Gianì, Marco Russo, Livia Manzella and Paolo Vigneri. *Molecular Alterations in Thyroid Cancer: From Bench to Clinical Practice.* Genes (Basel). 2019 Sep 13;10(9). pii: E709. **Impact Factor: 4,096.**
36. **Stefania Stella**, Michele Massimino, Elena Tirrò, Silvia Rita Vitale, Vincenzo Accurso, Adriana Puma, Maria Stella Pennisi, Sandra Di Gregorio, Chiara Romano, Francesco Di Raimondo, Sergio Siragusa and Livia Manzella. *Detection and Clinical Implications of a Novel BCR-ABL1 E12A2 Insertion/Deletion in a CML Patient Expressing the E13A2 Isoform.* Anticancer Res. 2019 Dec;39(12):6965-6971. doi: 10.21873/anticancerres.13918. **Impact Factor: 2,48.**
37. **Stefania Stella**, Enrico Maria Gottardi, Valeria Favout, Eva Barragan Gonzales, Santa Errichiello, Silvia Rita Vitale, Carmen Fava, Luigia Luciano, Fabio Stagno, Francesco Grimaldi, Lucrezia Pironi, Claudia Sargas Simarro, Paolo Vigneri and Barbara Izzo. *The Q-LAMP Method Represents a Valid and Rapid Alternative for the Detection of the BCR-ABL1 Rearrangement in Philadelphia-Positive Leukemias.* Int J Mol Sci. 2019 Dec 4;20(24). pii: E6106. doi: 10.3390/ijms20246106. **Impact Factor: 5,923.**
38. Michele Massimino, Elena Tirrò, **Stefania Stella (co-first author)**, Maria Stella Pennisi, Silvia Rita Vitale, Adriana Puma, Chiara Romano, Sandra Di Gregorio, Maria Anna Romeo, Francesco Di Raimondo and Livia Manzella. *Targeting BCL-2 as a Therapeutic Strategy for Primary p210BCR-ABL1-positive B-ALL Cells.* In Vivo. 2020 Mar-Apr;34(2):511-516. doi: 10.21873/invivo.11802. **Impact Factor: 2,155.**
39. Simona Soverini, Luana Bavaro, Caterina De Benedictis, Margherita Martelli, Alessandra Iurlo, Nicola Orofino, Simona Sica, Federica Sorà, Francesca Lunghi, Fabio Ciceri, Sara Galimberti, Claudia Baratè, Massimiliano Bonifacio, Luigi Scaffidi, Fausto Castagnetti, Gabriele Gugliotta, Francesco Albano, Antonella Vita Russo Rossi, Fabio Stagno, Francesco di Raimondo, Mariella D'Adda, Eros di Bona, Elisabetta Abruzzese, Gianni Binotto, Rosaria Sancetta, Marzia Salvucci, Isabella Capodanno, Mariella Girasoli, Sabrina Coluzzi, Immacolata Attolico, Caterina Musolino, Elisabetta Calistri, Mario Annunziata, Monica Bocchia, **Stefania**

- Stella**, Anna Serra, Santa Errichiello, Giuseppe Saglio, Fabrizio Pane, Paolo Vigneri, Flavio Mignone, Maria Antonella Laginestra, Stefano Aldo Pileri, Antonio Percesepe, Elena Tenti, Gianantonio Rosti, Michele Bacarani, Michele Cavo and Giovanni Martinelli. *Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study*. *Blood*. 2020 Feb 20;135(8):534-541. doi: 10.1182/blood.2019002969. **Impact Factor: 22,113.**
40. Michele Massimino, **Stefania Stella (co-first author)**, Elena Tirro', Maria Stella Pennisi, Silvia Rita Vitale, Adriana Puma, Chiara Romano, Sandra Di Gregorio, Cristina Tomarchio, Francesco Di Raimondo and Livia Manzella. *ABL1-Directed Inhibitors for CML: Efficacy, Resistance and Future Perspectives*. *Anticancer Res.* 2020 May;40(5):2457-2465. doi: 10.21873/anticancer.14215. Review. **Impact Factor: 2,48.**
 41. Uros Markovic, Anna Bulla, Salvatore Leotta, **Stefania Stella**, Maria Letizia Consoli, Loredana Tambè, Concetta Conticello, Francesco Di Raimondo and Fabio Stagno. *Second-line Dasatinib Therapy Improved Compliance and Deep Molecular Responses in Imatinib-intolerant Chronic Myeloid Leukemia Patients*. *Anticancer Res.* 2020 Sep;40(9):5313-5317. doi: 10.21873/anticancer.14538. **Impact Factor: 2,48.**
 42. **Stefania Stella**, Michele Massimino, Livia Manzella, Maria Stella Pennisi, Elena Tirrò, Chiara Romano, Silvia Rita Vitale, Adriana Puma, Cristina Tomarchio, Sandra Di Gregorio, Giuseppe Alberto Palumbo and Paolo Vigneri. *Molecular pathogenesis and treatment perspectives for hypereosinophilia and hypereosinophilic syndromes*. *Int J Mol Sci.* 2021 Jan 6;22(2):486. Doi: 10.3390/ijms22020486. Review. **Impact Factor: 5,923.**
 43. Elena Tirrò, Michele Massimino, Chiara Romano, Federica Martorana, Maria Stella Pennisi, **Stefania Stella**, Giuliana Pavone, Sandra Di Gregorio, Adriana Puma, Cristina Tomarchio, Silvia Rita Vitale, Livia Manzella and Paolo Vigneri. *Prognostic and Therapeutic Roles of the Insulin Growth Factor System in Glioblastoma*. *Front Oncol.* 2021 Feb 2; 10:612385. Doi: 10.3389/fonc.2020.612385. Review. **Impact Factor: 6,244.**
 44. Salvatore Leotta, Uros Markovic, Maria Cristina Piroso, **Stefania Stella**, Stefania Tringali, Massimo Martino, Giordina Specchia, Paola Carluccio, Antonio M. Risitano, Francesco Grimaldi, Ernesto Vigna, Fausto Palmieri, Raffaele Palmieri, Mario Annunziata, Giovanni Pisapia, Giulia Palazzo, Giulio Antonio Milone, Angelo Curto Pelle, Luca Scalise, Mary Ann Di Giorgio, Anna Bulla, Valerio Leotta, Francesco Di Raimondo and Giuseppe Milone. *The role of ponatinib in adult BCR-ABL1 positive acute lymphoblastic leukemia after allogeneic transplantation: a real-life retrospective multicenter study*. *Ann Hematol.* 2021 Jul;100(7):1743-1753. doi: 10.1007/s00277-021-04504-0. Epub 2021 Mar 28. **Impact Factor: 3,673.**
 45. Simona Soverini, Margherita Martelli, Luana Bavaro, Caterina De Benedictis, Cristina Papayannidis, Chiara Sartor, Federica Sorà, Francesco Albano, Sara Galimberti, Elisabetta Abruzzese, Mario Annunziata, Sabina Russo, Manuela Stulle, Annalisa Imovilli, Massimiliano Bonifacio, Elena Maino, Fabio Stagno, Claudia Maria Basilio, Erika Borlenghi, Claudio Fozza, Flavio Mignone, Roberta Minardi, **Stefania Stella**, Michele Bacarani, Michele Cavo and Giovanni Martinelli. *Next-generation sequencing improves BCR-ABL1 mutation detection in Philadelphia chromosome-positive acute lymphoblastic leukemia*. *Br J Haematol.* 2021 Apr; 193(2):271-279. Doi.org/10.1111/bjh.17301. Epub 2021 Jan 6. **Impact Factor: 6,99.**
 46. Silvia Rita Vitale, Federica Martorana, **Stefania Stella**, Gianmarco Motta, Nicola Inzerilli, Michele Massimino, Elena Tirrò, Livia Manzella and Paolo Vigneri. *PI3K inhibition in breast cancer: Identifying and overcoming different flavors of resistance*. *Crit Rev Oncol Hematol.* 2021 Jun; 162:103334. Doi:10.1016/j.critrevonc.2021.103334. Epub 2021 Apr 15. Review. **Impact Factor: 6,312.**
 47. **Stefania Stella**, Federica Martorana, Livia Manzella and Paolo Vigneri. *The other side of the coin: dissecting molecular mechanisms behind hereditary breast cancer in search of therapeutic opportunities*. *Transl Oncol.* 2021 Aug;14(8):101104. doi: 10.1016/j.tranon.2021.101104. Epub 2021 May 13. **Impact Factor: 4,243.**
 48. Federica Martorana, Gianmarco Motta, Giuliana, Pavone, Lucia Motta, Stefania Stella, Silvia Rita Vitale, Livia Manzella and Paolo Vigneri. *AKT Inhibitors: New Weapons in the Fight Against Breast Cancer?* *Front Pharmacol.* 2021 Apr 29; 12:662232. Doi: 10.3389/fphar.2021.662232. eCollection 2021. **Impact Factor: 5,81.**
 49. Michele Massimino, Elena Tirrò, **Stefania Stella**, Livia Manzella, Maria Stella Pennisi, Chiara Romano, Silvia Rita Vitale, Adriana Puma, Cristina Tomarchio, Sandra Di Gregorio, Agostino

- Antolino, Francesco Di Raimondo and Paolo Vigneri. *Impact of the Breakpoint Region on the Leukemogenic Potential and the TKI Responsiveness of Atypical BCR-ABL1 Transcripts*. *Front Pharmacol*. 2021 Jun 30; 12:669469. Doi: 10.3389/fphar.2021.669469. eCollection 2021. **Impact Factor: 5,81.**
50. Chiara Romano, Federica Martorana, Maria Stella Pennisi, **Stefania Stella**, Michele Massimino, Elena Tirrò, Silvia Rita Vitale, Sandra Di Gregorio, Adriana Puma, Cristina Tomarchio and Livia Manzella. *Opportunities and Challenges of Liquid Biopsy in Thyroid Cancer*. *Int J Mol Sci*. 2021 Jul 19;22(14):7707. doi: 10.3390/ijms22147707. **Impact Factor: 5,923.**
 51. **Stefania Stella**, Silvia Rita Vitale, Michele Massimino, Adriana Puma, Cristina Tomarchio, Maria Stella Pennisi, Elena Tirrò, Chiara Romano, Fabio Stagno, Francesco Di Raimondo and Livia Manzella. *A Novel System for Semiautomatic Sample Processing in Chronic Myeloid Leukaemia: Increasing Throughput without Impacting on Molecular Monitoring at Time of SARS-CoV-2 Pandemic*. *Diagnostics (Basel)*. 2021 Aug 20;11(8):1502. doi: 10.3390/diagnostics11081502. **Impact Factor: 3,706.**
 52. Michele Massimino, Paolo Vigneri, **Stefania Stella**, Elena Tirrò, Maria Stella Pennisi, Laura Nunziatina Parrinello, Calogero Vetro, Livia Manzella, Fabio Stagno and Francesco Di Raimondo. *Combined Inhibition of Bcl2 and Bcr-Abl1 Exercises Anti-Leukemia Activity but Does Not Eradicate the Primitive Leukemic Cells*. *J. Clin. Med*. 2021 Nov 29; 10(23): 5606. doi: 10.3390/jcm10235606. **Impact Factor: 4,242.**
 53. Alice Turdo, Miriam Gaggianesi, Simone Di Franco, Veronica Veschi, Caterina D'Accardo, Gaetana Porcelli, Melania Lo Iacono, Irene Pillitteri, Francesco Verona, Gabriella Militello, Alessio Zippo, Vittoria Poli, Luca Fagnocchi, Sven Beyes, **Stefania Stella**, Rossano Lattanzio, Naida Faldetta, Vincenzo L. Lentini, Rossana Porcasi, Giuseppe Pistone, Maria Rita Bongiorno, Giorgio Stassi, Ruggero De Maria and Matilde Todaro. *Effective targeting of breast cancer stem cells by combined inhibition of Sam68 and Rad51*. *Oncogene* 2022 Apr;41(15):2196-2209. Doi: 10.1038/s41388-022-02239-4. Epub 2022 Feb 25. **Impact Factor: 9.86.**
 54. Elena Tirrò, Federica Martorana, Giovanni Micale, Nicola Inzerilli, Rosaria Carciotto, Chiara Romano, Claudio Longhitano, Gianmarco Motta, Katia Lanzafame, **Stefania Stella**, Michele Massimino, Silvia Rita Vitale, Lucia Salvatorelli, Gaetano Magro, Livia Manzella and Paolo Vigneri. *Next generation sequencing in a cohort of patients with rare sarcoma histotypes: A single institution experience*. *Pathol Res Pract*. 2022 Apr; 232:153820. Doi: 10.1016/j.prp.2022.153820. Epub 2022 Feb 25. **Impact Factor: 3.25.**
 55. **Stefania Stella (first author)**, Silvia Rita Vitale, Federica Martorana, **Michele Massimino**, Giuliana Pavone, Katia Lanzafame, Sebastiano Bianca, Chiara Barone, Cristina Gorgone, Marco Fichera and Livia Manzella. *Mutational Analysis Of BRCA1 And BRCA2 Genes In Breast Cancer Patients From Eastern Sicily*. *Cancer Manag Res* 2022 Apr 5; 14:1341-1352. doi 10.2147/CMAR.S348529. eCollection 2022. **Impact Factor: 3,89.**
 56. Michele Massimino, **Stefania Stella**, Giovanni Micale, Lucia Motta, Giuliana Pavone, Giuseppe Broggi, Eliana Piombino, Gaetano Magro, Hector Jose Soto Parra, Livia Manzella and Paolo Vigneri. *Mechanistic Translation of Melanoma Genetic Landscape in Enriched Pathways and Oncogenic Protein-Protein Interactions*. *Cancer Genomics Proteomics*. May-Jun 2022; 19 (3):350-361. doi: 10.21873/cgp.20325. **Impact Factor: 4.069.**
 57. **Stefania Stella (first author)**, Silvia Rita Vitale, Fabio Stagno, Michele Massimino, Adriana Puma, Cristina Tomarchio, Maria Stella Pennisi, Elena Tirrò, Chiara Romano, Francesco Di Raimondo, Emma Cacciola and Livia Manzella. *Impact of Different Cell Counting Methods in Molecular Monitoring of Chronic Myeloid Leukemia Patients*. *Diagnostics (Basel)*. 2022 May 2(5), 1051; <https://doi.org/10.3390/diagnostics12051051>. **Impact Factor: 4.24.**
 58. **Stefania Stella (first author)**, Silvia Rita Vitale, Michele Massimino, Gianmarco Motta, Claudio Longhitano, Katia Lanzafame, Federica Martorana, Carmine Fazzari, Giada Maria Vecchio, Elena Tirrò, Nicola Inzerilli, Rosaria Carciotto, Livia Manzella, Michele Caruso and Paolo Vigneri. *Molecular Analysis of Luminal Androgen Receptor Reveals Activated Pathways and Potential Therapeutic Targets in Breast Cancer*. *Cancer Genomics Proteomics*. Jul-Aug 2022;19(4):464-476. doi: 10.21873/cgp.20333. **Impact Factor: 4.069.**

- Proceedings 18. Tirrò Elena, Stella Stefania, Conte Enrico, Palio Elisabetta, Manzella Livia, Vigneri Paolo, Messina Angelo. Silencing of BCR-ABL/JAK2- induced survivin sensitizes Imatinib resistant CML cells to hydroxyurea - Medimond International Proceedings of 4th International Conference on "Tumor Microenvironment: Progression, Therapy and Prevention" pag 31- 34.
- Editorial 19. Albano Francesco, Castagnetti Fausto, Galimberti Sara, Iurlo Alessandra, Serra Anna, Sica Simona, Soverini Simona, Stella Stefania. Next-Generation Sequencing nelle Leucemie PH+ - Manuale di Ematologia, Mattioli 2018.
- Presentation 20. Conference "Le basi molecolari delle malattie", Messina 20 Maggio 2005. "L'apoptosi indotta da BCR-ABL nucleare richiede p73". S. Stella, M.S. Pennisi, P.Vigneri, A. Aloisi, A. Messina.
21. Meeting Ordine Nazionale dei Biologi "La Biologia Molecolare nel laboratorio di Patologia Clinica". Siracusa 28 Maggio 2005. "Monitoraggio mediante Real Time PCR del trascritto BCR-ABL in pazienti affetti da Leucemia Mieloide Cronica". S. Stella.
22. Meeting Progetto Regionale AIRC Sicilia "CML Resistance to Imatinib Mesylate: Early Molecular Characterization and Alternative Therapeutic Approaches" (riunione conclusiva). Titolo della presentazione: "Riduzione dell'espressione di Survivina come potenziale approccio terapeutico per cellule di LMC resistenti all'Imatinib Mesilato". S. Stella.
23. XXIX National Congress SIP In Collaboration with the American Society for Investigative Pathology, 10-13 Settembre 2008. "Silencing of Survivin induced by a BCR-ABL/JAK2/STAT3 Pathway Kills CML Cells and Sensitizes IM-Resistant Clones To Hydroxyurea". S. Stella, E. Tirrò, E. Conte, E. Palio, L. Manzella, D. Altieri, A. Messina, P. Vigneri.
24. XXX National Congress Italian Society of Pathology, Salerno, 14-17 Ottobre 2010. "High BCR-ABL Expression Levels at Diagnosis May Predict Unfavorable CML Response to Imatinib Therapy". S. Stella, F. Stagno, S. Forte, V. Del Fabro, M. Massimino, F. Di Raimondo, L. Manzella, Messina, P. Vigneri.
25. 2° Meeting for Young researches "SIP YOUNG SCIENTISTS - Navigating the road to a successful career in Pathology Research", Bologna 24-25 Ottobre 2011. "Biological characterization of the activity of nuclear BCR-ABL". S. Stella, M.S. Pennisi, C. Romano, M. Massimino, A. Aloisi, L. Manzella, A. Messina and P. Vigneri.
26. CML Academy 2016, Bologna 18-19 Aprile 2016. "Le nuove metodologie per il monitoraggio". S. Stella e S. Soverini.
27. Investigator Meeting "Next in CML", Napoli 16 Maggio 2016. "Ponatinib e Necroptosis". S. Stella.
28. Conference "Dal Singolo Target ai Pannelli di Geni: Evoluzione delle Terapie e delle Tecnologie", Catania 26 Maggio 2016. "NGS per l'analisi mutazione nelle sindromi mieloproliferativi croniche". S. Stella.
29. 33° National Congress SIPMET, Montesilvano (PE), 4-6 Ottobre, 2016. "BCR-ABL1 doubling- and halving-times may predict CML Response to Tyrosine Kinase Inhibitors". S. Stella.
30. Conference SMART SCIENCE 2017 "L'Innovazione delle biotecnologie nella ricerca scientifica", Catania 26 - 27 Gennaio 2017. "Next Generation Sequencing (NGS) Versus Sanger Sequencing per lo screening Mutazione del Dominio Tirocinico-Chinasico di BCR-ABL". S. Stella.
31. Meeting SMART LAB 2017 "Innovazione nella diagnostica clinica molecolare", Catania 9 - 10 Febbraio 2017. "Comparazione tra metodica convenzionale e biopsia liquida in pazienti con carcinoma NSCLC metastatico". S. Stella.
32. "Educational meeting on NGS in Ph+ Leukemia", Milano 17 Maggio 2017. "Next Generation Sequencing: descrizione metodica e strumentazione". S. Stella.
33. "Educational meeting on NGS in Ph+ Leukemia", Roma 18 Maggio 2017. "Next Generation Sequencing: descrizione metodica e strumentazione". S. Stella.
- Presentation 34. "Educational meeting on NGS in Ph+ Leukemia", Seconda Edizione, Milano 16 Marzo 2018. "Modalità di refertazione e tempistiche" "Interpretazione del dato". S. Stella

35. "Educational meeting on NGS in Ph+ Leukemia", Seconsa Edizione, Roma 15 Marzo 2018. *"Modalità di refertazione e tempistiche"* *"Interpretazione del dato"*. S. Stella
36. Conference "Approccio Multidisciplinare alla Mastocitosi Sistemica". Catania, 09 Luglio 2020. *"Approccio del biologo molecolare per la diagnosi dei pazienti con mastocitosi Sistemica"*. S. Stella.
37. Conference "Approccio Multidisciplinare alla Mastocitosi Sistemica". Catania, 09 Luglio, 25 Settembre e 28 Ottobre 2020. *"Criteri per l'identificazione e la gestione dei pazienti con mastocitosi sistemica: suddivisione tra le diverse manifestazioni cliniche"*. S. Stella.
38. Conference "Approccio Multidisciplinare alla Mastocitosi Sistemica". Catania, 09 Luglio, 25 Settembre e 28 Ottobre 2020. *"Discussione e stesura di un percorso diagnostico terapeutico integrato (PDTA) per la diagnosi e la gestione dei pazienti con Mastocitosi Sistemica"*. S. Stella.
39. Conference "EVENTO REGIONALE MULTIDISCIPLINARE - Mastocitosi Sicilia". Catania, 28 Aprile 2021. *"Inquadramento molecolare della malattia"*. S. Stella.

Catania, 31.01.2023

